The modeled difference between groups ( solanezumab group minus placebo group ) in the change from baseline was -0.8 points for the ADAS-cog11 score ( 95 % confidence interval [ CI ] , -2.1 to 0.5 ; P = 0.24 ) and -0.4 points for the ADCS-ADL score ( 95 % CI , -2.3 to 1.4 ; P = 0.64 ) in EXPEDITION 1 and -1.3 points ( 95 % CI , -2.5 to 0.3 ; P = 0.06 ) and 1.6 points ( 95 % CI , -0.2 to 3.3 ; P = 0.08 ) , respectively , in EXPEDITION 2 .